Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. - Wikidata - wikimedia - TriplyDB

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.

http://www.wikidata.org/entity/Q37300183

about

Acute lymphoblastic leukaemia JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications Genomic profiling of B-progenitor acute lymphoblastic leukemia Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition Hematological disorders and leukemia in children with Down syndrome.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.IL-7 in human health and disease.Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia In search of targeted therapies for childhood cancer.Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?JAK Kinases in Health and Disease: An Update Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21.Constitutional aneuploidy and cancer predisposition.Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases Genomic profiling of high-risk acute lymphoblastic leukemia.A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.JAK2 inhibition for the treatment of hematologic and solid malignancies.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Genomics in acute lymphoblastic leukaemia: insights and treatment implications.Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.Philadelphia chromosome-like acute lymphoblastic leukemia.Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation.Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group.Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.

P2860

Q24602387-5CE494AA-8438-40B7-AFB2-7538381E1570 Q26782539-AEB40630-E3E6-4F47-832F-F52E754C17F2 Q26829976-AE7C490F-13EC-4D78-A6AE-F8B02365FED2 Q27683852-621B65CD-8602-4476-9424-E0CFDEE613C8 Q33398426-19422BF5-32C3-4435-A053-F968503BA715 Q33591867-435054BF-BCE5-4431-AA59-34318A92F4EA Q33636082-23702E6A-7FD0-41D1-B724-7115A46A453E Q33698398-AA687159-023D-4181-AC31-0256EE56B351 Q33938184-C840A679-4417-4532-85EB-53DE3E1A06A2 Q34065882-D50E6ECF-9C60-4199-BE24-5A3831436C60 Q34122298-A3444B74-7E40-4248-BB1A-C80CF2302CE9 Q34168482-5C4398F6-30A0-4331-8DC3-D8B7D57F139F Q34260682-CC2190C2-B0BB-4EFB-9733-75AF6C771013 Q34307423-AB39B96E-0D45-44D0-A6D6-D83D8C46710E Q35500533-8CA036FE-C98A-491C-A55B-3765E6DEBCEB Q35971733-EABA9053-4CF3-4614-80CA-21591A4E3BD2 Q36141916-93368D03-496A-4691-99C3-FBFBD6FC0875 Q36163029-2E33ADEC-1C50-406C-817C-F2C5BDC2B614 Q36285745-4E79D36C-1458-4B94-8C50-4BB08786EEFA Q36442514-34EF5B0B-8627-40B0-B2C6-3B907083FCC8 Q36681400-AC7E63EB-3C19-40CB-8DB1-5C97C9B945D2 Q37134129-8BAAE1C8-09CA-489A-BAB5-3109E548F5D1 Q37429718-99ADB358-E9E3-4ACE-9A3A-5B6A0752F8AF Q37440638-F89C3EC1-06FC-4D87-A1C9-5BE45EB44234 Q37687519-7D4DE69B-15EC-4944-A25B-1789EAFD8402 Q37782546-7026918F-422C-428B-8706-85B8B8D52391 Q37921836-BF0E616A-6EEE-433F-97B6-4072FF38D852 Q37935867-BE5945AB-EB3A-4340-B842-214EFB3EEE06 Q38001733-1F0B0EF6-BBDA-41C1-BD81-C0FF827893CF Q38097334-C521D5B5-3D1E-4BBB-9796-F62B7BDE3D8E Q38381463-E05FB4C7-AB29-4439-8743-69C1629864E5 Q39120515-B3B22C97-BB58-4147-B2E7-0836AA44512E Q39170500-8251E934-524A-453C-8B9E-591348DAECF2 Q43431904-C18E9B72-E9A9-486A-8C54-DE706E884DA7 Q44018556-666D3A4A-B234-403F-B47C-C28791FEA56F Q45723589-26924357-063C-4CCC-B08C-BBAB3E12ACA9 Q48326539-A4417FCA-C8CF-4CF1-805E-CB92834BBDFC Q53270825-BB1D571B-49FB-45EA-A6E2-B016BE7074DF Q54336349-1814FCA5-2013-405B-83CA-5B8EA8A6C032 Q54522930-BEA98EB7-E427-4A3E-8320-380832705C11

P2860

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.

http://www.wikidata.org/entity/Q37300183

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prevalence and clinical correl ...... acute lymphoblastic leukaemia.

@en

Prevalence and clinical correl ...... acute lymphoblastic leukaemia.

@nl

type

label

Prevalence and clinical correl ...... acute lymphoblastic leukaemia.

@en

Prevalence and clinical correl ...... acute lymphoblastic leukaemia.

@nl

prefLabel

Prevalence and clinical correl ...... acute lymphoblastic leukaemia.

@en

Prevalence and clinical correl ...... acute lymphoblastic leukaemia.

@nl

P1433

Q37300183-E56C3E5C-EE75-4A09-ADBC-7B3D707E54F2

P1476

Q37300183-6F48BEA5-AB59-49F7-8FB6-F771045C6969

P2093

Q37300183-500FAE93-D4CC-4DC1-A330-BC2992A186C7

Q37300183-941A6817-12F6-4298-A8BB-0D5ED76F2EFB

Q37300183-A67D64D6-DE33-458B-8258-61CAA16FD777

Q37300183-B301E567-D055-455F-AFD4-56DBBD5D8EBB

Q37300183-C98B1A6C-DD4B-4511-8A94-AA8C75C799D4

Q37300183-F4C4F0BF-4B7D-46F0-B6DC-633EA7E34DDF

Q37300183-FE6EEC78-35A1-49A8-BBAA-DD1C83390D36

P2860

Q37300183-2ED1064F-8D02-4187-A24A-6B8E22B1EDFF

Q37300183-49CE86DE-836D-41CF-972F-E649B5194910

Q37300183-9E821016-4A96-4AC9-8F0F-C59D5AF5862E

Q37300183-B61C7B0C-8CDA-4D9C-92DC-2771AECDD9AE

Q37300183-E4A50979-4C1E-4B96-8863-AD6045925BAC

Q37300183-FC5EC257-5E73-4A28-8BE5-DD15EEB5B0EC

P304

Q37300183-A5A88470-D28D-486D-9EB0-2552C9FB48FA

P31

Q37300183-4B99A64C-D349-4CDA-9691-C251412F9902

P356

Q37300183-9F7A672C-9639-4BBB-904F-88CD41FC9C4D

P407

Q37300183-68286497-F119-4694-B7C2-072F62F2BF9A

P433

Q37300183-2E250862-0C01-41C7-AA01-7757518D304B

P478

Q37300183-27E44AD1-5CC4-4B12-A916-822C213B9D46

P50

Q37300183-1E54D484-3C89-43DE-A0D6-A695F487D4F3

Q37300183-C37C4C02-D13A-4BE0-BD53-075FF861D521

Q37300183-E1483775-03BC-43C5-AE5C-8C94A222FE45

P577

Q37300183-0C9574B7-2A49-43A0-AA67-9C85FD2B70B5

P5875

Q37300183-D369FBCD-D34C-492A-B7A2-55E368A8A174

P698

Q37300183-8F8B4529-96A2-424A-B6F8-A7C2420E63A2

P921

Q37300183-EEB79E1E-C6DA-4798-8B15-0E0892ACA7D5

P932

Q37300183-32E0D5C7-CFEA-4600-A4FA-A5F5B0EFD285

P356

J.1365-2141.2008.07552.X

P1433

British Journal of Haematology

P1476

Prevalence and clinical correl ...... acute lymphoblastic leukaemia

@en

P2093

Amos Gaikwad

http://www.w3.org/2001/XMLSchema#string

Andrew J Carroll

http://www.w3.org/2001/XMLSchema#string

Cassia L Rye

http://www.w3.org/2001/XMLSchema#string

Karen R Rabin

http://www.w3.org/2001/XMLSchema#string

Meenakshi Devidas

http://www.w3.org/2001/XMLSchema#string

Shai Izraeli

http://www.w3.org/2001/XMLSchema#string

Sharon E Plon

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

P304

930-932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2008.07552.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

144

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23718096

http://www.w3.org/2001/XMLSchema#string

P698

19120350

http://www.w3.org/2001/XMLSchema#string

P921

P932

2724897

http://www.w3.org/2001/XMLSchema#string